IMW-001 is an IL-12-based immunocytokine engineered to bind and selectively activate intratumoral CD8⁺  T cells. In murine tumor models, IMW-001 achieves cure rates of 65-75% in tumors exceeding 400 mm³. In cynomolgus macaques, the molecule demonstrates a substantially improved safety profile and does not trigger systemic IFN-y release even at doses up to 50 mg/kg.